193 related articles for article (PubMed ID: 26057136)
21. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM
Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599
[TBL] [Abstract][Full Text] [Related]
22. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
24. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
[TBL] [Abstract][Full Text] [Related]
25. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
Egbon M; Ojo T; Aliyu A; Bagudu ZS
BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
[TBL] [Abstract][Full Text] [Related]
26. National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
Casey RM; Adrien N; Badiane O; Diallo A; Loko Roka J; Brennan T; Doshi R; Garon J; Loharikar A
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A10-A16. PubMed ID: 34593269
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.
Wei L; Xie X; Liu J; Zhao Y; Chen W; Zhao C; Wang S; Liao X; Shou Q; Qiu Y; Qiao Y; Saah AJ
Vaccine; 2019 Jun; 37(27):3617-3624. PubMed ID: 30122646
[TBL] [Abstract][Full Text] [Related]
31. HPV vaccination coverage in three districts in Zimbabwe following national introduction of 0,12 month schedule among 10 to 14 year old girls.
LaMontagne DS; Manangazira P; Marembo J; Chigodo C; Zvamashakwe C; Tshuma E; Marima E; Chindedza K; Ndlela E; Mooney J
Vaccine; 2022 Mar; 40 Suppl 1():A58-A66. PubMed ID: 34275674
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019.
Ahmed D; VanderEnde K; Harvey P; Bhatnagar P; Kaur N; Roy S; Singh N; Denzongpa P; Haldar P; Loharikar A
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A17-A25. PubMed ID: 34429233
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran.
Yaghoubi M; Nojomi M; Vaezi A; Erfani V; Mahmoudi S; Ezoji K; Zahraei SM; Chaudhri I; Moradi-Lakeh M
Value Health Reg Issues; 2018 May; 15():112-119. PubMed ID: 29698864
[TBL] [Abstract][Full Text] [Related]
34. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
Vetter KM; Geller SE
J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
[TBL] [Abstract][Full Text] [Related]
35. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
[TBL] [Abstract][Full Text] [Related]
37. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
[TBL] [Abstract][Full Text] [Related]
38. Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.
Garon JR; Mukavhi A; Rupfutse M; Bright S; Brennan T; Manangazira P; An Q; Loharikar A
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A30-A37. PubMed ID: 34144852
[TBL] [Abstract][Full Text] [Related]
39. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y
Vaccine; 2019 Feb; 37(6):889-897. PubMed ID: 30638797
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]